Company / Operating Cash Flow
NewAmsterdam Pharma Co N.V. Operating Cash Flow History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$147.8M
FY2025
5-year range
-$158.6M / $10.7M
FY2021-FY2025
Trend
+6.8%
vs FY2024
Sector context
#152 of 215
Health Care
What the data says
At -$148M, NewAmsterdam Pharma Co N.V.'s operating cash flow ranks #152 of 215 in the Health Care sector. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$148M.
Based on SEC 10-K filings.
-$148M in FY2025.
Declined from -$141M to -$148M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#152 of 215 in Health CareTop 71% of 215This company -$147.8M Sector average $661.2M
▼
-122.4% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 6.8% year-over-year.
- Ranks #152 out of 215 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$147.8M | +6.8% |
| FY2024 | -$158.6M | -12.3% |
| FY2023 | -$141.2M | -1424.1% |
| FY2022 | $10.7M | +136.1% |
| FY2021 | -$29.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026